CR1 in Alzheimer's disease
Xi-Chen Zhu1, Jin-Tai Yu, Teng Jiang
1Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Qingdao, China.
Molecular Neurobiology
|May 6, 2014
Summary
The complement component receptor 1 (CR1) gene is a significant risk factor for late-onset Alzheimer's disease (LOAD). Research highlights CR1's role in AD pathogenesis, including immune dysfunction and neuroinflammation.
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Late-onset Alzheimer's disease (LOAD) is a complex neurodegenerative disorder.
- The complement component receptor 1 (CR1) gene has emerged as a key genetic risk factor for LOAD.
- Understanding CR1's function is crucial for elucidating LOAD pathogenesis.
Purpose of the Study:
- To review current evidence on the role of CR1 in LOAD.
- To explore the relationship between CR1 polymorphisms and LOAD risk.
- To discuss CR1's impact on Alzheimer's disease (AD) pathology and neuroinflammation.
Main Methods:
- Literature review of recent studies on CR1 and LOAD.
- Analysis of CR1 structure, localization, and physiological functions.
- Summary of genetic association studies linking CR1 polymorphisms to LOAD risk.
Main Results:
- CR1 is a type-I transmembrane glycoprotein implicated in immune regulation.
- Specific CR1 polymorphisms are associated with an increased risk of developing LOAD.
- CR1 influences AD pathogenesis through amyloid-β pathology, tauopathy, and glial-mediated neuroinflammation.
Conclusions:
- CR1 plays a multifaceted role in the development of LOAD.
- Targeting CR1 pathways may offer novel therapeutic strategies for AD.
- Further research into CR1's function can advance AD prevention and treatment.
More Related Videos
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
9.8K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.6K
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K